Kyowa Kirin International

Kyowa Kirin International is the regional headquarters for the Europe, Middle East, and Africa (EMEA) operations of Kyowa Kirin, a global specialty pharmaceutical company based in Japan. The company was established following the 2011 acquisition of the Scottish firm ProStrakan Group and is currently headquartered in Galashiels, Scotland. It focuses on the development and commercialization of innovative therapies in core areas such as oncology, nephrology, central nervous system, and rare diseases. Key products in its portfolio include Crysvita for X-linked hypophosphatemia and Poteligeo for cutaneous T-cell lymphoma. Kyowa Kirin International leverages advanced antibody technologies, including POTELLIGENT technology, to address unmet medical needs. The organization plays a critical role in the parent company's global strategy to transform into a global specialty pharmaceutical powerhouse.